Action is the latest following Baldwin’s investigation into the extremely high prices these companies charge for inhalers ...

Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeu ...

AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

The blow fill seal technology market is expected to grow from its estimated USD 3,107.8 million in 2024 to USD 5,258.5 million in 2034. Between 2024 and 2034, sales are expected to increase at a ...

The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contributing ...

GSK has made the decision to withdraw Jesduvroq (daprodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, from the US market.

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Sweid One is a pivotal project for us, designed to raise the bar for commercial office space within JLT,” said Maher Sweid, ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...